PMID- 25409499
OWN - NLM
STAT- MEDLINE
DCOM- 20150713
LR  - 20220409
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 11
DP  - 2014
TI  - Low serum cartonectin/CTRP3 concentrations in newly diagnosed type 2 diabetes 
      mellitus: in vivo regulation of cartonectin by glucose.
PG  - e112931
LID - 10.1371/journal.pone.0112931 [doi]
LID - e112931
AB  - OBJECTIVES: Cartonectin is a novel adipokine of the C1q complement/TNF-related 
      protein (CTRP) superfamily, with glucose lowering effects, anti-inflammatory and 
      cardio-protective properties. We sought to investigate circulating cartonectin 
      concentrations in subjects with type 2 diabetes mellitus (T2DM) as well as age 
      and BMI matched control subjects. We also examined the effects of a 2 hour 75 g 
      oral glucose tolerance test (OGTT) on serum cartonectin concentrations in T2DM 
      subjects. DESIGN: Cross-sectional study [newly diagnosed (first discovery, not on 
      any treatments) T2DM (n = 47) and control (n = 63) subjects]. Serum cartonectin 
      was measured by ELISA. RESULTS: Serum cartonectin concentrations were 
      significantly lower in patients with T2DM compared to controls (P<0.05). 
      Furthermore, serum cartonectin was significantly negatively correlated with 
      glucose and CRP, and significantly positively correlated with leptin, in all 
      subjects (n = 110). When subjected to multiple regression analysis, none of these 
      variables were predictive of serum cartonectin (P>0.05). There were no 
      significant correlations in T2DM subjects (n = 47). In control subjects (n = 63), 
      serum cartonectin was significantly negatively correlated with CRP, and 
      significantly positively correlated with insulin, HOMA-IR and leptin. However, 
      when subjected to multiple regression analysis, none of these variables were 
      predictive of serum cartonectin (P>0.05). Finally, serum cartonectin 
      concentrations were significantly lower in T2DM subjects after a 2 hour 75 g OGTT 
      (P<0.01). CONCLUSIONS: Cartonectin may serve as a novel biomarker for the 
      prediction and early diagnosis of T2DM patients. Furthermore, cartonectin and/or 
      pharmacological agents that increase circulating cartonectin levels can represent 
      a new therapeutic field in the treatment of T2DM patients. Further research is 
      needed to clarify these points.
FAU - Ban, Bo
AU  - Ban B
AD  - Department of Endocrine and Metabolic Diseases, Jining Medical College Affiliated 
      Hospital, Jining Medical University, Jining, Shandong, P.R. of China.
FAU - Bai, Bo
AU  - Bai B
AD  - Neurobiology Institute, Jining Medical University, Jining, Shandong, P.R. of 
      China.
FAU - Zhang, Manman
AU  - Zhang M
AD  - Department of Endocrine and Metabolic Diseases, Jining Medical College Affiliated 
      Hospital, Jining Medical University, Jining, Shandong, P.R. of China; School of 
      Medicine, Shandong University, Jinan, Shandong, P.R. of China.
FAU - Hu, Jiamiao
AU  - Hu J
AD  - Warwick Medical School, University of Warwick, Coventry, West Midlands, United 
      Kingdom.
FAU - Ramanjaneya, Manjunath
AU  - Ramanjaneya M
AD  - Warwick Medical School, University of Warwick, Coventry, West Midlands, United 
      Kingdom.
FAU - Tan, Bee K
AU  - Tan BK
AD  - Warwick Medical School, University of Warwick, Coventry, West Midlands, United 
      Kingdom; Department of Obstetrics and Gynaecology, Birmingham Heartlands and 
      Solihull Hospitals, Heart of England NHS Foundation Trust, Birmingham, West 
      Midlands, United Kingdom.
FAU - Chen, Jing
AU  - Chen J
AD  - Neurobiology Institute, Jining Medical University, Jining, Shandong, P.R. of 
      China; Warwick Medical School, University of Warwick, Coventry, West Midlands, 
      United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141119
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (C1QTNF3 protein, human)
RN  - 0 (Tumor Necrosis Factors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis
MH  - Female
MH  - Glucose/administration & dosage/*metabolism
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tumor Necrosis Factors/*blood
PMC - PMC4237345
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/11/20 06:00
MHDA- 2015/07/15 06:00
PMCR- 2014/11/19
CRDT- 2014/11/20 06:00
PHST- 2014/06/12 00:00 [received]
PHST- 2014/10/16 00:00 [accepted]
PHST- 2014/11/20 06:00 [entrez]
PHST- 2014/11/20 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
PHST- 2014/11/19 00:00 [pmc-release]
AID - PONE-D-14-26284 [pii]
AID - 10.1371/journal.pone.0112931 [doi]
PST - epublish
SO  - PLoS One. 2014 Nov 19;9(11):e112931. doi: 10.1371/journal.pone.0112931. 
      eCollection 2014.